Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFF-R CAR-T cells in CD19-negative B-cell lymphoma
NCT07369492Phase 1Recruiting
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAFF-R CAR T cells in B cell lymphoma, sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 1 month and Adverse Events and Serious Adverse Events at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
BAFF-R CAR T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07369492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369492.